And soon it starts to add up. This week the NIH announced a pretty cool partnership with the private pharma industry. The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot project. 11 pharma companies (AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer) will contribute $1M each for five years. The NIH will contribute $160 million. The goal: “to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments.” Sweet. If you want to read what pharma PR folks have been up to you can read their responses here. For the top 10 private-public immuno-oncology collaborations, look here.
The answer is Beau. How do we know? Because the Cancer Moonshot has been renamed the “Beau Biden Cancer Moonshot” in honor of the VP’s late son who died from brain cancer. Armed with $1.8B in funding, VP Biden recently gave an update on the project. One highlight is how the National Cancer Institute created the Genomic Data Commons, which archives cancer patient data using Amazon’s cloud computing software. Researchers have accessed this information about 80 million times, so that is a lot. In another initiative, companies like AZ, Novartis, Pfizer, and Celgene, just to name a few, are contributing to the Blood Profiling Atlas in Cancer (BloodPAC) consortium. Go team.
Well, President Trump… hey, where are you going? Don’t go yet! The President released his 2018 budget proposal. (We have saved you others’ analyses. This is the source document). Along with many other departments, the NIH may find itself wondering where 20% of its money went (go to p. 22 of the document). Also, prices are going up at the FDA. Plan on submitting a drug for approval? That might cost you double next year. InsightCity recommends you spend a few minutes in this document. It’s surprisingly readable. Also, the President and Congress have until October to come to an agreement so there’s little chance the proposal survives intact. There’s probably a better chance that the government shuts down or that pigs fly.
We’ve all had cuts and scrapes and most of them have healed pretty quickly. Well, the chronic wounds (i.e. diabetic ulcers) that affect 6 million US patients per year require a little more attention than antiseptic and a band aid. So much in fact that the US health care system spends an estimated $20B annually on treating these wounds. Cue the brilliant minds at Drexel University who have created a small, battery-powered, wearable device that uses low-frequency ultrasound to heal wounds. This caught the attention of the NIH who has awarded Drexel $3M to test the therapy over the next five years. Batteries make terrible band aids, but 6M patients a year means they’ll be in a lot of medicine cabinets.
The Zika virus has crossed the U.S. southern border and will soon be taking jobs away from American viruses. With Zika now active in the U.S., and not just from travelers abroad, the search intensifies for a vaccine to prevent the spread. A new category of therapies, DNA vaccines, appears all the rage. It’s new because no DNA vaccine has ever been approved for sale. DNA vaccine trials are currently underway by the NIH, Inovio Pharmaceuticals, and GeneOne Life Science. Still barely interested in Zika? Here’s NASA’s forecast for its spread in the U.S. Or maybe you’re not worried because you live in Europe? Well then, here’s a fun read. You’re welcome.